UniXell Biotechnology key facts
- Developer of cellular therapy designed for human pluripotent stem cells.
- It has raised $66.6M; the latest was Early Stage VC ($7.2M) in Feb 2026.
- Notable investors include GL Ventures, CDH Investments, Tencent Investment, Pudong Capital, Shanghai Pudong Venture Capital — 21 tracked in total.
- Status: Privately Held (backing).
Who backs UniXell Biotechnology
21+Membership and data by Private Market View
- ·The complete investor list: 21 names
- ·Watch UniXell Biotechnology: the Monday email on marks, rounds and moves
UniXell Biotechnology funding rounds
No funding rounds for UniXell Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
UniXell Biotechnology investors
21 investors are on record for UniXell Biotechnology, including GL Ventures, CDH Investments, Tencent Investment and Pudong Capital.
About UniXell Biotechnology
Developer of cellular therapy designed for human pluripotent stem cells. The company offers unmet medical needs, including neurodegenerative diseases and rare diseases, and it has developed multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology and high-precision gene editing, thereby providing effective treatment solutions for patients afflicted with neurodegenerative disorders, rare diseases, and tumors.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 40
- Website
- unixell.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
UniXell Biotechnology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.